L-Tryptophan Depletion Using a New Bioreactor: A Possible New Cancer Therapy DOI Open Access

Journal of Clinical & Experimental Immunology, Journal Year: 2023, Volume and Issue: 8(3)

Published: July 20, 2023

Not all cancer therapeutic strategies known to date are adequate for patients. Most of them followed by a high rate severe side effects and complications. L-Tryptophan metabolism plays key role in organism development, as well the occurrence development tumors. By degrading certain amino acids, tumor growth can be limited while maintaining body´s normal nutritional requirements. The L-tryptophan depletion bioreactor is described possible new method therapy. an essential acid that has been recognized important nutrient its removal lead destruction cells. Tumor cells or human cannot synthesize therefore resistance unlikely develop. also constituent different biomolecules such Sero-tonin, Melatonin, needed other synthesis processes cell growth. enzymes with three iso-enzymes called tryptophan chain oxydase (TSO) I, II, III have molecular weights effectiveness. All TSO heme catalyze essentially similar reactions involving substrate. most effective type III. A column, which contained TSO, immobilized on silica beats bioreactor, was integrated plasmapheresis unit tested it animals. In sheep rabbits, plasma shown at 95% 100% rates respectively single pass through bioreactor. 20 lines, there were efficacies. Brest medulloblastoma showed greatest efficacy degrading. gene technology production from Pseudomonas associated formation endotoxins. These endotoxins must eliminated. Bioreactors developed treat diseases successfully low effects. combination available thera-pies possible.

Language: Английский

Smart Delivery Vehicles for Cancer: Categories, Unique Roles and Therapeutic Strategies DOI Creative Commons
Yiyu Zeng, Yijun Gao, Liming He

et al.

Nanoscale Advances, Journal Year: 2024, Volume and Issue: 6(17), P. 4275 - 4308

Published: Jan. 1, 2024

Chemotherapy and surgery remain the primary treatment modalities for cancers; however, these techniques have drawbacks, such as cancer recurrence toxic side effects, necessitating more efficient strategies. Recent advancements in research medical technology provided novel insights expanded our understanding of development; consequently, scholars investigated several delivery vehicles therapy to improve efficiency patient outcomes. Herein, we summarize types smart therapeutic carriers elaborate on mechanism underlying drug delivery. We reveal advantages treatment, focus their effectiveness immunotherapy, discuss application combination with other emerging strategies treatment. Finally, bottlenecks encountered development suggest directions future research. This review will promote progress facilitate related

Language: Английский

Citations

4
Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy DOI Open Access
Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117858 - 117858

Published: Feb. 16, 2025

Language: Английский

Citations

0
PD-1/CTLA-4 antibody AK104 in advanced solid tumors after PD/PD-L1 treatment failure: A retrospective cohort study DOI Creative Commons
Jun Yi, Herbert Yu,

Yun Shu

et al.

Medicine, Journal Year: 2025, Volume and Issue: 104(10), P. e41548 - e41548

Published: March 7, 2025

AK104 is a novel antibody targeting programmed cell death protein 1 (PD-1)/cytotoxic T-lymphocyte-associated 4. This study aimed to evaluate the safety, tolerability, and efficacy of in treating patients with advanced solid tumors who failed prior 1/programmed death-ligand (PD/PD-L1) therapies. Clinical data from 135 PD/PD-L1 therapies were retrospectively analyzed. Patients received at dose 6 mg/kg every 2 weeks. Baseline demographic characteristics, clinical outcomes, adverse reactions, overall survival, progression-free quality life assessments Following treatment, 17.78% achieved partial response, while 80.74% experienced stable disease, resulting disease control rate 98.52%. The 1- 2-year survival rates 48.15% 31.11%, months year 53.33% 28.15%, respectively. Post-treatment, significant improvements quality-of-life scores, as assessed by European Organisation for Research Treatment Cancer Quality Life Questionnaire-Core 30 EuroQol 5 Dimensions Visual Analog Scale, observed post-treatment. Immune-related events common, affecting 85.19% patients, diarrhea, enteritis, pneumonia, thyroid dysfunction being most frequently reported. demonstrated ability induce responses, extend enhance had previously PD-1/PD-L1 therapies, underscoring its potential promising therapeutic option. However, high incidence immune-related necessitates vigilant monitoring management maximize utility. Further prospective studies are warranted validate these findings broader patient populations.

Language: Английский

Citations

0
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota DOI
Ali Rahimi,

Zeinab Baghernejadan,

Ali Hazrati

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 186, P. 118014 - 118014

Published: March 31, 2025

Language: Английский

Citations

0
Targeting Innate Immunity in Glioma Therapy DOI Open Access
Andrew G. Gillard, Dong Ho Shin,

Lethan A Hampton

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 947 - 947

Published: Jan. 12, 2024

Currently, there is a lack of effective therapies for the majority glioblastomas (GBMs), most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types cancers, they had limited success improving overall survival GBM patients. Therefore, advancing treatment requires deeper understanding molecular cellular mechanisms that cause resistance to immunotherapy. Further insights into innate immune response are crucial developing more potent treatments tumors. Our review provides brief overview immunity. In addition, we provide discussion current aimed at boosting immunity gliomas. These approaches encompass strategies activate Toll-like receptors, induce stress responses, enhance response, leverage interferon type-I therapy, therapeutic antibodies, checkpoint natural killer (NK) cells, oncolytic virotherapy, manipulate microbiome. Both preclinical clinical studies indicate better governing could immunotherapy reinforce effects chemotherapy radiotherapy. Consequently, comprehensive against cancer should lead prognoses increased

Language: Английский

Citations

2
Immune Checkpoints in Endometriosis—A New Insight in the Pathogenesis DOI Open Access
Dorota Suszczyk, Wiktoria Skiba, Anna Pawłowska

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 6266 - 6266

Published: June 6, 2024

Endometriosis (EMS) is an oestrogen-dependent, chronic disease affecting women of a reproductive age. One the important factors involved in development this complex disorders associated with functioning immune system. Recent evidence has shown that EMS changes systemic and local immunity, including functional disturbances effector antigen-presenting cells. reasons for imbalance can be improper expression checkpoints (ICPs). ICPs their ligands are responsible maintaining self-tolerance modulation initiation, duration, magnitude response cells normal tissues to avoid tissue damage. Considering nature co-stimulatory or co-inhibitory signalling between APCs, we hypothesise cells' activity caused by may lead serious system patients endometriosis. Moreover, both upregulation downregulation implicated process, reduced against endometrial implants process. In narrative review, discuss, first time, key findings from emerging literature, describing associations possible implication pathogenesis

Language: Английский

Citations

2
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade DOI Open Access
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 161, P. 114436 - 114436

Published: Feb. 24, 2023

Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic virotherapy also emerged as a strategy to fight against cells both via lysis malignant and activating immune responses. Accepted logical strategy, combination monoclonal antibodies particularly programmed death-1 (PD-1) death-ligand 1 (PD-L1) is introduced improve clinical responses checkpoint inhibitors (ICIs). Accordingly, Talimogene laherparepvec (T-VEC) received approval for use, while number oncolytic Adenoviruses (Ads) are being investigated in trials malignancies. Combination Ads with PD-1/PD-L1 have shown potentials promoting ICIs, changing tumor microenvironment, inducing long-term protection tumor, survival among mice models Regarding increasing importance therapy cancers, this review we decide outline recent studies field.

Language: Английский

Citations

4
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report DOI Open Access
Carolin Krekeler, Klaus Wethmar, Jan‐Henrik Mikesch

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(15), P. 12056 - 12056

Published: July 27, 2023

DNA mismatch repair deficient (dMMR) and microsatellite instable (MSI) metastatic colorectal cancer (mCRC) can be successfully treated with FDA- EMA-approved immune checkpoint inhibitors (ICI) pembrolizumab nivolumab (as single agents targeting the anti-programmed cell death protein-1 (PD-1)) or combinations of a PD-1 inhibitor ipilimumab, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeting antibody. The best treatment strategy beyond progression on single-agent ICI therapy remains unclear. Here, we present case 63-year-old male Lynch-syndrome-associated, instability-high (MSI-H) mCRC who achieved rapid normalization his tumor markers complete metabolic remission (CMR), currently lasting for ten months, sequential combination ipilimumab followed by maintenance after anti-PD-1 therapy. was well-tolerated, no immune-related adverse events occurred. To our knowledge, this is first sustained in an MSI-H patient initially progressing Thus, dMMR patients might benefit from regimens even long-term responses. However, further sophistication clinical algorithms MSI-mCRC urgently needed.

Language: Английский

Citations

4
Metformin facilitates anti-PD-L1 efficacy through the regulation of intestinal microbiota DOI
Xiaopeng Zhao, Chuang Liu, Licheng Peng

et al.

Genes and Immunity, Journal Year: 2023, Volume and Issue: 25(1), P. 7 - 13

Published: Dec. 13, 2023

Language: Английский

Citations

4
Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review DOI
Hori Ghaneialvar, Saleheh Jahani, Elham Hashemi

et al.

Human Immunology, Journal Year: 2024, Volume and Issue: 86(1), P. 111209 - 111209

Published: Dec. 10, 2024

Language: Английский

Citations

1